



Neuren (NEU) – ASX Announcement

2 May 2025

Neuren appoints Daryl DeKarske to executive team

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that Daryl DeKarske has joined the Neuren executive team as Chief Regulatory Officer. Daryl has extensive experience leading global regulatory strategy and execution, as well as technical expertise in both non-clinical and clinical product development and executive management of R&D. He has broad experience in orphan drug indications in multiple therapeutic areas, including CNS, across his most recent regulatory affairs leadership positions at Shire, Acadia and Horizon Therapeutics. At Acadia, Daryl played an important role in the Phase 3 development and New Drug Application for trofinetide.

Neuren CEO Jon Pilcher commented: "I am very pleased to welcome Daryl to the Neuren team. He has ideal experience and his broad expertise will make a big difference as we advance NNZ-2591 in multiple indications for global markets, led by the Phase 3 program in Phelan-McDermid syndrome."

About Neuren

Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.

DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.

Neuren's second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome.

Contact:

investorrelations@neurenpharma.com

Jon Pilcher, CEO: +61 438 422 271

ASX Listing Rules information

This announcement was authorized to be given to the ASX by the Board of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124

Forward-looking Statements

This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.